Matrix metalloproteinase inhibitor MMI-166 inhibits lymphogenous metastasis in an orthotopically implanted model of lung cancer

Molecular Cancer Therapeutics

Volumn 4, Issue 9, 2005, Pages 1409-1416

  Fujino, Haruhiko ^a   Kondo, Kazuya ^a   Ishikura, Hisashi ^a   Maki, Hideo ^b   Kinoshita, Hidetaka ^a   Miyoshi, Takanori ^a   Takahashi, Yuji ^a   Sawada, Naruhiko ^a   Takizawa, Hiromitsu ^a   Nagao, Taeko ^a   Sakiyama, Shoji ^a   Monden, Yasumasa ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b SHIONOGI AND CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE INHIBITOR; MMI 166; UNCLASSIFIED DRUG; MATRIX METALLOPROTEINASE; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE MODEL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIFESPAN; LUNG CANCER; LYMPH NODE METASTASIS; MALE; MEDIASTINUM; METASTASIS INHIBITION; MOUSE; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; ANIMAL; CELL CULTURE; COMPARATIVE STUDY; DRUG ANTAGONISM; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METASTASIS; MOUSE MUTANT; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL RATE; VASCULARIZATION;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE MODELS, ANIMAL; HUMANS; INJECTIONS, SUBCUTANEOUS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MATRIX METALLOPROTEINASES; MICE; MICE, SCID; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; SULFONAMIDES; SURVIVAL RATE; TUMOR CELLS, CULTURED;

EID: 33644698160     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0031     Document Type: Article

References (28)

1. Cotran IRS, Kumar V, Robbins SL. Neoplasia. In: Schoen FJ, editor. Robbins pathologic basis of disease. 5th ed. Philadelphia: WB Saunders; 1994. p. 241-303.
2. Moore FD, Jr., Lee SJ. Staging and prognostic factors: Non-small cell lung cancer. In: Pass IH, Mitchell BJ, Johnson HD, Turrisi TA, editors. Lung cancer: principles and practice. Philadelphia: Lippincott-Raven Publishers; 1996. p. 481-94.
3. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997; 111: 1710-7.
4. Liotta LA, Tryggvason K, Garbisa S, et al. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980;284:67-8.
5. Tokuraku M, Sato H, Murakami S, et al. Activation of the precursor of gelatinase A/72 kDa type IV collagenase/MMP-2 in lung carcinomas correlates with the expression of membrane-type matrix metalloproteinase (MT-MMP) and with lymph node metastasis. Int J Cancer 1995;64: 355-9.
6. Passlick B, Sienel W, Seen-Hibler R, et al. Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer. Clin Cancer Res 2000;6:3944-8.
7. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991; 64:327-36.
8. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996;2: 689-92.
9. Itoh T, Tanioka M, Yoshida H, et al. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 1998;58: 1048-51.
10. Itoh T, Tanioka M, Matsuda H, et al. Experimental metastasis is suppressed in MMP-9-cleficient mice. Clin Exp Metastasis 1999;17: 177-81.
11. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 2001;93:178-93.
12. Maekawa R, Maki H, Wada T, et al. Anti-metastatic efficacy and safety of MMI-166, a selective matrix metal loprote inase inhibitor. Clin Exp Metastasis 2000;18:61 - 6.
13. Matsuoka T, Yashiro M, Sawada T, et al. Effect of a matrix metalloproteinase inhibitor on a lymph node metastatic model of gastric cancer cells passaged by orthotopic implantation. J Exp Clin Cancer Res 2001;20:213 - 8.
14. Yamashita T, Fujii M, Tomita T, et al. The inhibitory effect of matrix metalloproteinase inhibitor ONO-4817 on lymph node metastasis in tongue carcinoma. Anticancer Res 2003;23:2297 - 302.
15. Ishikura H, Kondo K, Miyoshi T, et al. Artificial lymphogenous metastatic model using orthotopic implantation of human lung cancer. Ann Thorac Surg 2000;69:1691 - 5.
16. Miyoshi T, Kondo K, Ishikura H, et al. SCID mouse lymphogenous metastatic model of human lung cancer constructed using orthotopic inoculation of cancer cells. Anticancer Res 2000;20:161 - 4.
17. Kondo K, Kinoshita H, Ishikura H, et al. Activation of matrix Metalloproteinase-2 Is correlated with Invasiveness in thymic epithelial tumors. J Surg Oncol 2001;76:169-75.
18. Saiki H, Murata J, Watanabe K, et al. Inhibition of tumor cell invasion by Ubenimex (Bestatin) in vitro. Jpn J Cancer Res 1989;80: 873-8.
19. Ishikura H, Kondo K, Miyoshi T, et al. Suppression of mediastinal metastasis by uracil-tegafur or cis-diamminedichloroplatinum (II) using a lymphogenous metastatic model in a human lung cancer cell line. Clin Cancer Res 2001;7:4202-8.
20. Hyder SM, Stancel GM. Regulation of angiogenic growth factors in the female reproductive tract by estrogens and progestins. Mol Endocrinol 1999; 13:806-11.
21. Shepherd FA, Sridhar SS. Angiogenesis inhibitors under study for the treatment of lung cancer. Lung Cancer 2003;41:S63-72.
22. Matsushita A, Onda M, Uchida E, Maekawa R, Yoshioka T. Antitumor effect of a new selective matrix metalloproteinase inhibitor, MMI-166, on experimental pancreatic cancer. Int J Cancer 2001;92: 434-40.
23. Katori H, Babe Y, Imagawa Y, et al. Reduction of in vivo tumor growth by MMI-166, a selective matrix metalloproteinase inhibitor, through inhibition of tumor angiogenesis in squamous cell carcinoma cell lines of head and neck. Cancer Lett 2002;178:151-9.
24. Yoshida S, Shimizu E, Ogura T, Takada M, Sone S. Stimulatory effect of reconstituted basement membrane components (Matrigel) on the colony formation of a panel of human lung cancer cell lines in soft agar. J Cancer Res Clin Oncol 1997;123:301-9.
25. Bao L, Matsumura Y, Baban D, Sun Y, Tarin D. Effects of inoculation site and Matrigel on growth and metastasis of human breast cancer cells. Br J Cancer 1994;70:228-32.
26. Bonfil RD, Vinyals A, Bustuoabad OD, et al. Stimulation of angiogenesis as an explanation of Matrigel-enhanced tumorigenicity. Int J Cancer 1994;58:233-9.
27. Oba K, Konno H, Tanaka T, et al. Prevention of liver metastasis of human colon cancer by selective matrix metal loprotei nase inhibitor MMI-166. Cancer Lett 2002; 175:45-51.
28. Fridman R, Kibbey MC, Royce LS, et al. Enhanced tumor growth of both primary and established human and murine tumor cells in athymic mice after coinjection with matrigel. J Natl Cancer Inst 1991; 83:769-74.